Thomson Reuters

Current Opinion in Drug Discovery & Development is a bimonthly review journal that has established itself as a unique journal encompassing all chemical aspects of drug R&D, from the initial concept stage, through to process development.

SUBJECT DIVISION

The subject of drug discovery and development is divided into six major sections, each of which is reviewed once a year

• The Chemistry of Metabolic and Toxicological Processes
• The Chemistry of Biological Products
• The Management of Chemical and Biological Information
• The Chemistry of Drug Design and Lead Optimization
• The Chemistry of Biological Processes
• The Chemistry of Process Development

SELECTION OF TOPICS TO BE REVIEWED

Section Editors, who are major authorities in the field, divide their section into a number of topics, ensuring that the field is comprehensively covered and that all issues of current importance are emphasized. Section Editors recommend reviews from authorities on each topic that they have selected.

"Essential reading for every drug R&D chemist"

-- Paul S Anderson, DuPont Pharmaceutical Company

With Current Opinion in Drug Discovery & Development, you can:

• Gain an intelligent overview on current advances in drug discovery and development in a clear and readable form.
  
• Follow the progress made in each area from year to year, systematically reviewing the highlights.
• View all the chemical processes within the drug product cycle, from the initial concept stage through to process development.
• Read timely commentary on a selection of the most interesting papers from the great wealth of original publications, annotated by experts.
  

Why choose Current Opinion in Drug Discovery & Development?

Current Opinion in Drug Discovery & Development is designed to give you an intelligent overview of the most important developments across this entire field of research. We make it easier for you to follow the progress made in each area from year to year by dividing the whole subject into sections and systematically reviewing the highlights.

The journal encompasses all of the chemical processes within the drug product cycle, from the initial concept stage, through to process development.

Discoveries of new chemical entities, intermediates, synthetic pathways, formulations and the latest developments in enabling technologies disclosed within primary literature and patents are discussed. It provides a unique forum for the discussion of current developments in the field.

The journal contains the views of experts in the form of editorial overviews, review articles, annotated paper and patent selections, and a web watch selection.

EACH ISSUE CONTAINS

Paper and Patent alerts
Commentary on a selection of recently published papers and patents, identified as being of particular interest.

Web alert
A selection of World Wide Web sites relevant to the contents of Current Opinion in Drug Discovery & Development is included in each issue.

Editorial overview
Short overviews in which an area of interest to the pharmaceutical industry is critically reviewed in the context of recent developments.

Reviews
Concise reviews in which authors present recent developments in their subject, emphasizing the aspects that, in their opinion, are most important. In addition, they provide short annotations to the cited papers that they consider to be the most interesting from all those published in their topic. Papers chosen by an author as being 'of special interest' or 'of outstanding interest' are clearly identified in the reference list at the end of each review.

Annual indexes
In the last issue of each volume, cumulative indexes of contents, subjects and authors are provided.

Current Opinion in Drug Discovery & Development contains contributions from internationally recognized leaders of their fields. All contributions are invited and peer-reviewed by an Editorial Board of distinguished members of the scientific community. The journal has a pyramidal structure of Editors in Chief, Editorial Board, Section Editors and reviewers.

EDITORS IN CHIEF

Paul J Reider (USA)
David Brown (USA)
Keith James (USA)
The Editors have overall responsibility for the content and editorial development of the journal.

SECTION EDITORS

The Section Editors are internationally recognized leaders of their field. They are responsible for the sections of the journal, and divide each section into a number of topics, ensuring that the field is comprehensively covered and that all issues of current importance are emphasized. The Section Editors write a short editorial overview at the beginning of each issue to introduce the reviews and to draw the reader's attention to any particularly interesting developments.

The Chemistry of Metabolic and Toxicological Processes
Dale E Johnson (USA), Dennis A Smith (UK) & B Kevin Park (UK)

The Chemistry of Biological Products
James McAlpine (Canada), David Ecker (USA) & Alfredo Romano (Switzerland)

The Management of Chemical and Biological Information
Peter Gund (USA), Ed Maliski (USA) & Frank Brown (USA)

The Chemistry of Drug Design and Lead Optimization
Manoj C Desai (USA) & Samuel Chackalamannil (USA)

The Chemistry of Biological Processes
John A Lowe (USA), Phil Jones (UK) & David M Wilson (UK)

The Chemistry of Process Development
Pat N Confalone (USA), John A Grosso (USA) & Joseph Fortunak (USA)